Solara Active Pharma Reports Strong Q4 Turnaround with 15.20% Stock Surge
Solara Active Pharma spurts after reporting turnaround Q4 perfromance
Business Standard
Image: Business Standard
Solara Active Pharma Sciences' stock surged 15.20% to ₹584.85 after reporting a consolidated net profit of ₹9.60 crore in Q4 FY26, a turnaround from a loss of ₹2.10 crore in the same quarter last year. Revenue from operations increased by 41.86% to ₹387.29 crore, driven by strong performance in its base business and Ibuprofen segment.
- 01The company's revenue from the base business grew 36% year-over-year to ₹307 crore.
- 02Revenue from the Ibuprofen business rose 61% year-over-year, totaling ₹849 crore.
- 03Solara reported an EBITDA increase of 21% to ₹61.7 crore in Q4 FY26.
- 04The company faced challenges in the Ibuprofen segment, which reported a negative 21% EBITDA margin.
- 05Sandeep Rao, managing director & CEO, highlighted a strategic pivot towards sustainable and profitable growth.
Advertisement
In-Article Ad
Solara Active Pharma Sciences experienced a significant turnaround in its financial performance for the fourth quarter of FY26, with its stock price rising 15.20% to ₹584.85 following the announcement of a consolidated net profit of ₹9.60 crore, contrasting sharply with a loss of ₹2.10 crore in Q4 FY25. Revenue from operations soared by 41.86%, reaching ₹387.29 crore, largely fueled by a 36% increase in the base business and a remarkable 61% rise in the Ibuprofen segment, which generated ₹849 crore. Despite these gains, the company reported a full-year consolidated net loss of ₹7.41 crore for FY26, compared to a profit of ₹0.54 crore in FY25. EBITDA rose 21% to ₹61.7 crore, although the EBITDA margin declined to 15.8% from 18.3% year-over-year. CEO Sandeep Rao noted the company's strategic shift towards sustainable growth, while acknowledging ongoing challenges in the Ibuprofen business, which operates at a negative 21% EBITDA margin. To address these challenges, the company has engaged bankers to explore strategic options for the Ibuprofen segment.
Advertisement
In-Article Ad
The company's improved financial performance may lead to increased investor confidence and potential job stability within the organization.
Advertisement
In-Article Ad
Reader Poll
Do you think Solara Active Pharma's strategic pivot will improve its profitability in the long run?
Connecting to poll...
More about Solara Active Pharma Sciences
Read the original article
Visit the source for the complete story.


